Paclitaxel by 72-Hour Continuous Infusion Followed by Bolus Intravenous Ifosfamide or Epirubicin: Results of Two Phase I Studies | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Paclitaxel by 72-Hour Continuous Infusion Followed by Bolus Intravenous Ifosfamide or Epirubicin: Results of Two Phase I Studies

Oncology (2001) 60 (2): 116–122.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance

Yong Wha Moon
Joo Hyuk Sohn
Hye Jin Choi
Hyun Chang
Byeong-Woo Park
Seung Il Kim
Seho Park
Ja Seung Koo
Yong Tai Kim
Jae Kyung Roh
Hyun Cheol Chung
Joo-Hang Kim

Cancer Chemotherapy and Pharmacology (2010) 66 (3): 425.

Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: A Pediatric Oncology Group study (POG 9376)

James I. Geller
Donna Wall
John Perentesis
Susan M. Blaney
Mark Bernstein

Pediatric Blood & Cancer (2009) 52 (3): 346.

Design and Development of New Combinations of the CMF Agents with Taxanes (Paclitaxel or Docetaxel) in Advanced Breast Cancer: A Feasibility Study

Giorgio Cocconi
Stefania Salvagni
Rodolfo Passalacqua
Francesco Ferrozzi
Roberta Camisa

Tumori Journal (2004) 90 (3): 280.